Details for 2012732263

Up to date per 01.04.2026

Actions

Title / Product Name

TUMORSPEZIFISCHEN KOMPLEMENTABHÄNGIGEN ZYTOTOXIZITÄT (CDC) ANTIKÖRPER ERZEUGERT DURCH VERABREICHUNG VON ONKOLYTISCHEN VACCINIAVIREN, ZUR BEHANDLUNG VON KREBS

Status

Deleted

Protection Type

European Patent

(AT-) Application Number

2012732263

EP Publication Number

2661278

E-Number

1144623

Language

PCT Number

US12020173

Publication Date

13.11.2013 A

19.06.2019 B1

Registration Date

19.06.2019

AT Publication Date

15.07.2019

Application Date

04.01.2012

Registration Number

Priorities

04.01.2011

201161429622 P

IPC

A61K 35/768 20150101AFI20181114BHEP

Maximum Duration of Protection

04.01.2032

Owner

SillaJen Biotherapeutics, Inc.450 Sansome Street, Suite 650 San Francisco, CA 94111US

Sillajen, Inc.307 Hyowon IC Building Pusan National University San 30 Busan 609-735KR

Representative

No representatives present

Inventor

KIRN, David444 La Verne Avenue Mill Valley California 94941US

BELL, John501 Smyth Road Ottawa Ontario K1H 8L6CA

BREITBACH, Caroline2655 Polk Street Apartment 406 San Francisco California 94109US

MOON, Anne450 Sansome Street 16th Floor San Francisco California 94111US

HWANG, Tae-HoWoo Sung Bestopia 9-601 DongRaeGu BoCheonDong Busan 607-751KR

LEE, Yu Kyoung106-1302 Dongwon royal duke Apt Hwamyeong-dong Buk-gu Busan 616-120KR

KIM, Mi-kyung503 Song Hyeon Damirang Apt. 22-1 Minrak-dong Suyeong-gu Busan 613-827KR